Liquid Biopsy for Detection of Driver Mutation in NSCLC

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

200 participants

Study Classification

OBSERVATIONAL

Study Start Date

2015-10-31

Study Completion Date

2020-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to evaluate the diagnostic and prognostic efficacy of liquid biopsy in different specimens and in different methods compared with tissue detection .

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Therapeutic ResistAnce and Clonal Evolution Assessed With Liquid Biopsy of NSCLC Patients in China

NCT03059641

Lung Neoplasms Lung Cancer, Nonsmall Cell Adenocarcinoma of Lung +1 more

COMPLETED

Liquid Biopsy in Advanced Oligometastatic NSCLC Receiving Surgery

NCT05648370

Non-small Cell Lung Cancer Oligometastatic Disease

UNKNOWN

Multicenter Observational Study of Chinese Non-Small Cell Lung Cancer (NSCLC) Patients With Rare Driver Gene Mutation

NCT04137718

Chinese Non-Small Cell Lung Cancer

UNKNOWN

To Establish a Molecular Typing System for Early Diagnosis of Lung Cancer

NCT05432128

Lung Cancer

RECRUITING

LIquid BIopsies in Patients Presenting Non-small Cell Lung Cancer

NCT02511288

Carcinoma, Non-Small-Cell Lung

RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Collect plasma and other specimens from patients who are newly diagnosed with NSCLC or with drug-resistant and plan to receive gene detection to complete the diagnostic test for liquid biopsy .Participants who come from diagnostic test and plan to receive tyrosine kinase inhibitors (TKI) therapy will be collected plasma and other specimens every month during the regiments and monitor the changes of driver motion to predict the prognosis of targeted therapy.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Non Small Cell Lung Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

cohort 1

Participants are recruited for diagnostic test

detection of driver mutation

Intervention Type GENETIC

participants are received gene detection via the liquid biopsy

cohort 2

participants are recruited for follow-up

detection of driver mutation

Intervention Type GENETIC

participants are received gene detection via the liquid biopsy

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

detection of driver mutation

participants are received gene detection via the liquid biopsy

Intervention Type GENETIC

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* patients newly diagnosed with NSCLC confirmed by tissue biopsy and going to receive the detection of gene mutation or patients have obtained drug-resistance after receiving molecular target therapy and plan to re-biopsy.
* Age ≥ 18 years
* newly diagnosed patients have not received TKI and chemotherapy
* patients who are drug-resistant have not received next-generation TKI

* patients from cohort1 with sensitive driver mutation and plan to receive TKI therapy
* patients will have regular follow-up in Chinese people liberation army general hospital every month.

Exclusion Criteria

* patients who have more than one type of carcinoma
* patients who reject to sign the informed consent from

cohort 2

* patients who are refused to provide the informed consent from

Minimum Eligible Age

18 Years

Maximum Eligible Age

85 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No